| Welcome
| Karl Mahler, Head of Investor Relations and Roche Group Planning | PDF |
| Pharma Strategy: Sustainable growth, more patient benefits, and less cost to society
| Bill Anderson, Chief Executive Officer Roche Pharmaceuticals | PDF |
| Commercial Opportunities
| Teresa Graham, Head of Pharma Global Product Strategy | PDF |
| Late Stage Pipeline Oncology & Non-malignant Hematology
| Levi Garraway, Chief Medical Officer and Head Global Product Development | PDF |
| Late Stage Pipeline Neuroscience
| Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development | PDF |
| Late Stage Pipeline Immunology & Ophthalmology
| Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy | PDF |
| Infectious Disease: A close look at the HBV pipeline
| John Young, Global Head of Infectious Diseases, Roche Pharma Research & Early Development | PDF |
| Late Stage Infectious Diseases: Influenza & SARS-CoV-2
| Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy | PDF |